350 related articles for article (PubMed ID: 21784190)
21. Eldecalcitol for the treatment of osteoporosis.
Noguchi Y; Kawate H; Nomura M; Takayanagi R
Clin Interv Aging; 2013; 8():1313-21. PubMed ID: 24101867
[TBL] [Abstract][Full Text] [Related]
22. Importance of alfacalcidol in clinical conditions characterized by high rate of bone loss.
Reginster JY; Lecart MP; Richy F
J Rheumatol Suppl; 2005 Sep; 76():21-5. PubMed ID: 16142847
[TBL] [Abstract][Full Text] [Related]
23. Overview of the clinical efficacy and safety of eldecalcitol for the treatment of osteoporosis.
Cui L; Xia W; Yu C; Dong S; Pei Y
Arch Osteoporos; 2022 May; 17(1):74. PubMed ID: 35513519
[TBL] [Abstract][Full Text] [Related]
24. Alfacalcidol versus plain vitamin D in the treatment of glucocorticoid/inflammation-induced osteoporosis.
Ringe JD; Faber H; Fahramand P; Schacht E
J Rheumatol Suppl; 2005 Sep; 76():33-40. PubMed ID: 16142849
[TBL] [Abstract][Full Text] [Related]
25. The safety and effectiveness profile of eldecalcitol in a prospective, post-marketing observational study in Japanese male patients with osteoporosis.
Kondo S; Kakihata H; Nishida Y; Furuno Y; Kobayashi Y; Tabata H; Nomura M
J Bone Miner Metab; 2019 Mar; 37(2):292-300. PubMed ID: 29532248
[TBL] [Abstract][Full Text] [Related]
26. Spotlight on eldecalcitol in osteoporosis.
Sanford M; McCormack PL
Drugs Aging; 2012 Jan; 29(1):69-71. PubMed ID: 22191725
[TBL] [Abstract][Full Text] [Related]
27. A randomized, double-blind, multicenter, placebo-controlled study to evaluate the efficacy and safety of oral salmon calcitonin in the treatment of osteoporosis in postmenopausal women taking calcium and vitamin D.
Henriksen K; Byrjalsen I; Andersen JR; Bihlet AR; Russo LA; Alexandersen P; Valter I; Qvist P; Lau E; Riis BJ; Christiansen C; Karsdal MA;
Bone; 2016 Oct; 91():122-9. PubMed ID: 27462009
[TBL] [Abstract][Full Text] [Related]
28. Prevention of bone loss and vertebral fractures in patients with chronic epilepsy--antiepileptic drug and osteoporosis prevention trial.
Lazzari AA; Dussault PM; Thakore-James M; Gagnon D; Baker E; Davis SA; Houranieh AM
Epilepsia; 2013 Nov; 54(11):1997-2004. PubMed ID: 24010637
[TBL] [Abstract][Full Text] [Related]
29. Vitamin D3 analogs for the treatment of osteoporosis.
Hagino H
Can J Physiol Pharmacol; 2015 May; 93(5):327-32. PubMed ID: 25853632
[TBL] [Abstract][Full Text] [Related]
30. Superiority of alfacalcidol over plain vitamin D in the treatment of glucocorticoid-induced osteoporosis.
Ringe JD; Dorst A; Faber H; Schacht E; Rahlfs VW
Rheumatol Int; 2004 Mar; 24(2):63-70. PubMed ID: 14513268
[TBL] [Abstract][Full Text] [Related]
31. Eldecalcitol and calcitriol stimulates 'bone minimodeling,' focal bone formation without prior bone resorption, in rat trabecular bone.
Saito H; Takeda S; Amizuka N
J Steroid Biochem Mol Biol; 2013 Jul; 136():178-82. PubMed ID: 23069645
[TBL] [Abstract][Full Text] [Related]
32. The safety and effectiveness profile of eldecalcitol in a prospective, post-marketing observational study in Japanese patients with osteoporosis: interim report.
Saito H; Kakihata H; Nishida Y; Yatomi S; Nihojima S; Kobayashi Y; Tabata H; Nomura M
J Bone Miner Metab; 2017 Jul; 35(4):456-463. PubMed ID: 27699492
[TBL] [Abstract][Full Text] [Related]
33. Three-year denosumab treatment in postmenopausal Japanese women and men with osteoporosis: results from a 1-year open-label extension of the Denosumab Fracture Intervention Randomized Placebo Controlled Trial (DIRECT).
Sugimoto T; Matsumoto T; Hosoi T; Miki T; Gorai I; Yoshikawa H; Tanaka Y; Tanaka S; Fukunaga M; Sone T; Nakano T; Ito M; Matsui S; Yoneda T; Takami H; Watanabe K; Osakabe T; Okubo N; Shiraki M; Nakamura T
Osteoporos Int; 2015 Feb; 26(2):765-74. PubMed ID: 25403903
[TBL] [Abstract][Full Text] [Related]
34. Efficacy of combined treatment with alendronate (ALN) and eldecalcitol, a new active vitamin D analog, compared to that of concomitant ALN, vitamin D plus calcium treatment in Japanese patients with primary osteoporosis.
Sakai A; Ito M; Tomomitsu T; Tsurukami H; Ikeda S; Fukuda F; Mizunuma H; Inoue T; Saito H; Nakamura T;
Osteoporos Int; 2015 Mar; 26(3):1193-202. PubMed ID: 25592133
[TBL] [Abstract][Full Text] [Related]
35. [Frontiers in vitamin D; Basic research and clinical application. Effect of eldecalcitol on bone structure].
Ito M
Clin Calcium; 2011 Nov; 21(11):119-25. PubMed ID: 22040828
[TBL] [Abstract][Full Text] [Related]
36. Vitamin D analogs versus native vitamin D in preventing bone loss and osteoporosis-related fractures: a comparative meta-analysis.
Richy F; Schacht E; Bruyere O; Ethgen O; Gourlay M; Reginster JY
Calcif Tissue Int; 2005 Mar; 76(3):176-86. PubMed ID: 15692726
[TBL] [Abstract][Full Text] [Related]
37. Efficacy of denosumab co-administered with vitamin D and Ca by baseline vitamin D status.
Sugimoto T; Matsumoto T; Hosoi T; Shiraki M; Kobayashi M; Okubo N; Takami H; Nakamura T
J Bone Miner Metab; 2020 Nov; 38(6):848-858. PubMed ID: 32671481
[TBL] [Abstract][Full Text] [Related]
38. Multifunctional and potent roles of the 3-hydroxypropoxy group provide eldecalcitol's benefit in osteoporosis treatment.
Ono Y
J Steroid Biochem Mol Biol; 2014 Jan; 139():88-97. PubMed ID: 24139874
[TBL] [Abstract][Full Text] [Related]
39. VITamin D supplementation in renAL transplant recipients (VITALE): a prospective, multicentre, double-blind, randomized trial of vitamin D estimating the benefit and safety of vitamin D3 treatment at a dose of 100,000 UI compared with a dose of 12,000 UI in renal transplant recipients: study protocol for a double-blind, randomized, controlled trial.
Courbebaisse M; Alberti C; Colas S; Prié D; Souberbielle JC; Treluyer JM; Thervet E
Trials; 2014 Nov; 15():430. PubMed ID: 25376735
[TBL] [Abstract][Full Text] [Related]
40. Relationship between baseline characteristics and response to risedronate treatment for osteoporosis: data from three Japanese phase III trials.
Mawatari T; Muraoka R; Iwamoto Y
Osteoporos Int; 2017 Apr; 28(4):1279-1286. PubMed ID: 27900428
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
